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MEF2 transcription factors are well-established
regulators of muscle development. We have
discovered an unanticipated role for MEF2C in
the neural crest, where tissue-specific inactiva-
tion results in neonatal lethality due to severe
craniofacial defects. We show that MEF2C is
required for expression of the Dlx5, Dlx6, and
Hand2 transcription factor genes in the bran-
chial arches, and we identify a branchial arch-
specific enhancer in the Dlx5/6 locus, which is
activated synergistically by MEF2C and Dlx5,
demonstrating that these factors interact to
induce transcription. Mef2c and Dlx5/6 also in-
teract genetically. Mice heterozygous for either
Dlx5/6 or Mef2c are normal at birth and survive
to weaning. By contrast, heterozygosity for both
Mef2c and Dlx5/6 results in defective palate
development and neonatal lethality. Taken
together, the studies presented here define a
feed-forward transcriptional circuit between
the MADS-box transcription factor MEF2C and
the homeodomain transcription factors Dlx5
and Dlx6 in craniofacial development.
INTRODUCTION
Neural crest (NC) cells originate from the dorsal neural
tube at the border between the neural plate and the lateral
epidermis (Knecht and Bronner-Fraser, 2002; Trainor,
2005). When induced by contact-mediated signals, NC
precursor cells undergo an epithelial-to-mesenchymal
transition, migrate throughout the developing embryo, and
give rise to various tissues, including the dorsal root
and sympathetic ganglia, the glial cells of the peripheral
and enteric nervous systems, melanocytes, and skeletal
elements of the face and head (Knecht and Bronner-
Fraser, 2002; Le Douarin et al., 2004; Trainor, 2005).
Numerous congenital disorders are due to improper
development of the NC and its derivatives, includingDevelocraniofacial defects, which account for one-third of all
congenital anomalies (Farlie et al., 2004; Trainor, 2005).
Several transcription factors are known to be required
for craniofacial development (Cobourne, 2000; Depew
et al., 2005). Among these, the homeodomain transcrip-
tion factors Dlx5 and Dlx6 are expressed in the NC-
derived ectomesenchyme of the first and second bran-
chial arches, and inactivation of Dlx5 and Dlx6 results in
mice that have numerous craniofacial defects (Beverdam
et al., 2002; Depew et al., 2002). Dlx6 is a direct transcrip-
tional activator of the Hand2 gene, which encodes a basic
helix-loop-helix (bHLH) transcription factor, in the first and
second branchial arches via a conserved branchial arch
enhancer element (Charite et al., 2001). Hand2 enhancer
null mice exhibit cleft palate and hypoplasia of the
mandible, among other craniofacial malformations (Yana-
gisawa et al., 2003). It is known that expression of both
Dlx6 and Hand2 in the branchial arch mesenchyme re-
quires endothelin signaling, but other components of this
pathway, including the transcription factors required for
activation of Dlx5 and Dlx6, are unknown (Charite et al.,
2001; Clouthier et al., 2000; Ruest et al., 2004; Thomas
et al., 1998).
The myocyte enhancer factor 2 (MEF2) family of tran-
scription factors has four members in vertebrates,
MEF2A–D (Black and Olson, 1998; McKinsey et al., 2002).
MEF2 proteins bind to a consensus DNA-binding element
known as a MEF2 site as homo- and heterodimers and
interact with other transcription factors to function as
both positive and negative regulators of gene expression,
in part through their association with class II histone
deacetylases (HDACs) (McKinsey et al., 2001). Mef2c is
the firstmember of theMEF2 family to be expressedduring
development, and Mef2c null mice die at embryonic day
9.5 (E9.5) with severe defects in cardiac and vascular
development (Edmondson et al., 1994; Lin et al., 1997,
1998). Although MEF2C is widely appreciated for its role
in the development of muscle lineages, its expression ad-
jacent to the neural folds at E8.5 in early NC development
has been reported previously (Edmondson et al., 1994),
but its function in the NC has not been investigated.
In the present study, we used a conditional gene target-
ing approach in mice to inactivateMef2c in the NC, which
results in lethality at birth due to upper airway obstruction.pmental Cell 12, 645–652, April 2007 ª2007 Elsevier Inc. 645
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hypoplasia or loss of the majority of the skeletal elements
of the face and skull. We show that the transcription factor
genes Dlx5, Dlx6, and Hand2 are not expressed in the NC
component of the branchial arches in Mef2c NC condi-
tional knockout embryos, and we identify a MEF2-depen-
dent transcriptional enhancer in the Dlx5/6 locus that is
sufficient to direct expression to the branchial arches
in vivo, establishingMEF2C as a direct transcriptional reg-
ulator of the Dlx6-Hand2 pathway in the NC. Furthermore,
theDlx5/6 enhancer identified in these studies is activated
synergistically by MEF2C and Dlx5, indicating that these
factors interact to regulate transcription. We also show
thatMef2c and Dlx5/6 interact genetically. Mice heterozy-
gous for either Dlx5/6 orMef2c are normal, whereas mice
heterozygous for both Mef2c and Dlx5/6 do not survive
and exhibit defective palate development. These studies
highlight a previously unappreciated role for MEF2C in
craniofacial development and identify a novel, feed-
forward transcriptional circuit between MEF2C and Dlx5/
6 in craniofacial development.
RESULTS
Mice LackingMef2c Function in the Neural Crest Die
at Birth Due to Upper Airway Obstruction
To determine the function of MEF2C in the NC, we condi-
tionally inactivated a floxed allele ofMef2c by usingWnt1-
Cre transgenic mice (Danielian et al., 1998; Vong et al.,
2005). Animals lacking Mef2c in the NC were born at
expected Mendelian ratios and were animated and re-
sponsive to touch. However, Mef2c conditional knockout
mice quickly became cyanotic, and 100% of these ani-
mals died within an hour of birth (Figure 1A).
The hearts, vasculature, and diaphragms of Mef2c NC
null mice showed no differences in grossmorphology, his-
tology, or marker gene expression compared to control
littermates (data not shown). However, neonates lacking
Mef2c function in the NC exhibited a posterior cleft of
the palate (Figure 1B), a constricted airway, and defective
positioning of the tongue near the back of the oral cavity
compared to control littermates (Figures 1C and 1D).
These defects occurred with 100% penetrance in knock-
out animals (n = 63) and in none of the littermate controls.
Knockout animals were tracheostomized with a 30G nee-
dle to bypass the upper airway, which resulted in recovery
from cyanosis and restoration of viability prior to humane
euthanasia (data not shown), demonstrating that mice
lacking Mef2c in the NC die at birth from asphyxiation
caused by upper airway obstruction.
Mef2c Function Is Required in the Neural Crest
for Craniofacial Development
Skulls from Mef2c NC conditional knockout neonates ex-
hibited several defective or missing craniofacial struc-
tures, including a hypoplastic mandible, zygomatic arch,
and temporal bone, compared to control littermates (Fig-
ure 1, compare [E] and [G] to [F] and [H]). Additionally, the
coronoid, condular, and angular processes of the mutant646 Developmental Cell 12, 645–652, April 2007 ª2007 Elseviermandibles were severely hypoplastic when compared
to littermate controls, and the tympanic ring was absent
in mice lacking Mef2c function in the NC (Figures 1G
Figure 1. Mef2c Is Required for Craniofacial Development
(A) Mice lacking Mef2c function in the neural crest have misshapen
heads (arrowhead) and die from asphyxiation within an hour of birth.
(B) Mef2c conditional knockout animals have a cleft of the posterior
palate (asterisk).
(C and D) Sagittal sections through the heads of (D)Mef2c neural crest
conditional knockout and (C) littermate control neonates show that the
upper airway is constricted in the conditional knockout compared to
control littermates (arrowheads).
(E–J) Skeleton preparations of neonatal and fetal mice stained with
alizarin red and alcian blue show that (F, H, and J) Mef2cflox/; Wnt1-
CreTg/0 skulls have multiple craniofacial defects compared to (E, G,
and I) littermate controls. Arrowheadsmark the location of the tympanic
ring in a (E) control skull and its absence in the (H)mutant skull. (E and F)
Bars of equal size show that the mutant mandible is markedly shorter
than the control. (G and H) Magnified view of the temporal region of
(G) control and (H)mutant skulls showing the (1) tympanic ring, (2) zygo-
matic bone, (3) mandibular processes, and (4) temporal bone pro-
cesses. Note that each of these structures is hypoplastic or missing
in Mef2c conditional knockout mice. (I and J) Delayed ossification in
Mef2c neural crest knockout mice at E16.5. Note the calcified bone in
(I) control, but not in (J) mutant. In (I) and (J), arrowheadsmarkMeckel’s
cartilage, and arrows mark the developing maxilla.Inc.
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Meckel’s cartilage and extensive ossification in themandi-
ble and maxilla (Figure 1I). By contrast, Mef2c NC knock-
out embryos exhibited hypoplastic Meckel’s cartilage and
a lack of ossification, as well as hypoplasia of other future
skeletal elements in the skull (Figure 1J). The differences
in skeletal development could be observed as early as
E13.5, a time prior to the onset of ossification, when
Meckel’s cartilage was already hypoplastic in conditional
knockout animals (data not shown). Taken together, these
results clearly establish that MEF2C function is required in
the NC for proper craniofacial development.
Branchial Arch Expression of Dlx5, Dlx6,
and Hand2 Requires MEF2C
In order to place MEF2C into a pathway for craniofacial
development, we examined the expression of several
transcription factor genes required for craniofacial devel-
opment at E9.5, which is the time when Mef2c is
expressed in the NC component of the branchial arches
and developing craniofacial mesenchyme (Figures 2A
and 2B). Notably, Dlx5, Dlx6, and Hand2 expression in
the first and second branchial arches was almost com-
pletely absent in Mef2c NC knockout mice compared to
control littermates at E9.5 (Figures 2C–2H; Figures S1A–
S1D, see the Supplemental Data available with this article
online). Prx1 null mice also have a similar craniofacial
phenotype to Mef2c NC conditional mice (Martin et al.,
1995). However, no differences were observed in Prx1
expression in Mef2c NC knockout and control embryos
(Figures S1E and S1F), indicating that branchial arch de-
velopment in general was not defective at this stage,
and that Prx1 is not a downstream target of MEF2C. No
differences were observed in the Wnt1-Cre fate map be-
tween NC knockout and control embryos in a ROSA26R
lacZ reporter background (Soriano, 1999), indicating that
the contribution of NC cells to the branchial arches and
viscerocranium was not grossly defective (Figures 2I and
2J). Likewise, no obvious changes were observed in
proliferation or apoptosis between knockout and control
embryos at E9.5 or E10.5 (Figures S1G–S1J). Taken to-
gether, these results suggest that the requirement for
Mef2c is in the postmigratory NC, and that MEF2C is an
upstream regulator of the Dlx6-Hand2 pathway in cranio-
facial development.
A Novel, Branchial Arch Enhancer from the Dlx5/6
Locus Is Directly Activated by MEF2C
Dlx6 is closely linked to Dlx5 in the mouse genome (Zeru-
cha et al., 2000), and deletion of both genes results in
very severe craniofacial defects. Inactivation of Dlx5/6 in
mice results in loss of Hand2 expression in the branchial
arches at E9.5, and Dlx6 has been shown to be a direct
transcriptional regulator of Hand2 through a conserved
enhancer in theHand2 locus (Beverdam et al., 2002; Char-
ite et al., 2001; Depew et al., 2002; Ruest et al., 2004).
Since Dlx5, Dlx6, and Hand2 were downregulated in the
absence of Mef2c function in the NC, we hypothesized
that MEF2C might directly regulate these genes. To iden-Develotify potential transcriptional enhancers from these genes,
we analyzed all of the conserved, noncoding sequences
in the Dlx5/6 and Hand2 loci for MEF2 sites, and we iden-
tified a deeply conserved element immediately upstream
of the Dlx6 coding sequence (Figure 3A) that contained
four highly conserved MEF2 sites and multiple potential
homeodomain protein (Hox)-binding sites (Figure 3B).
We tested this region of the Dlx5/6 locus for enhancer ac-
tivity by cloning it into the Hsp68-lacZ reporter plasmid
and using this construct to generate transgenic embryos.
This novel region of the Dlx5/6 locus directed expres-
sion to the first and second branchial arches at E9.5
(Figure 3C) in a pattern very similar to the endogenous
Dlx5 and Dlx6 expression patterns in the arches (Figures
2C and 2E).
All four of the candidate MEF2 sites in the Dlx5/6 locus
were bound byMEF2C in EMSA, although only the MEF2–
3 and MEF2–4 sites exhibited robust binding in vitro (data
not shown). To determine if the Dlx6 enhancer was re-
sponsive to MEF2 activation via its conserved MEF2 sites,
we tested a Dlx6-TK-lacZ reporter construct for MEF2C
trans-activation in 3T3 cells (Figure 3D). Cotransfection
with a MEF2C-VP16 expression plasmid resulted in 12-
fold greater activation of the Dlx5/6 reporter than control
cotransfections (Figure 3D, lane 4), and this activation
was dependent on the presence of intactMEF2 sites since
mutation of the four sites resulted in a complete loss of
activation of the enhancer element by MEF2C (Figure 3D,
lane 6). Taken together, these results demonstrate that the
MEF2 sites in this novel Dlx5/6 branchial arch enhancer
are functional and further support the notion that Dlx5
and Dlx6 are direct transcriptional targets of MEF2C via
this enhancer element.
Cooperative Activation of the Dlx5/6 Branchial Arch
Enhancer by MEF2C and Dlx5
The presence of multiple conserved Hox sites, combined
with the presence of functional MEF2 sites in the Dlx5/6
branchial arch enhancer, suggested that this enhancer
might also be activated by Dlx proteins themselves. We
tested this possibility and the possibility that MEF2C
might participate in a feed-forward transcriptional circuit
with Dlx5/6 by activating their expression and then coop-
erating with them to amplify Dlx5/6 expression (Figure 3E).
Indeed, Dlx5 activated expression of the Dlx5/6 enhancer
more than 50-fold (Figure 3E, lane 5). Furthermore, under
conditions in which wild-type MEF2C activated the en-
hancer only 3-fold (Figure 3E, lane 4), cotransfection of
Dlx5 and MEF2C resulted in clear synergy by activating
reporter expressionmore than 400-fold (Figure 3E, lane 6).
Genetic Interaction between Mef2c and Dlx5/6
Results in Neonatal Lethality in Compound
Heterozygous Mice
The transcriptional synergy between MEF2C and Dlx5
suggested that these genes might interact. Therefore,
we crossed Dlx5/6+/ mice with Mef2c+/ mice to test
for genetic interaction. Because Dlx5 and Dlx6 are closely
linked, the two genes have been deleted together inpmental Cell 12, 645–652, April 2007 ª2007 Elsevier Inc. 647
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Arches Requires Mef2c
(A and B) (A) Whole-mount and (B) sagittal section in situ hybridization
showing endogenousMef2c expression in wild-type embryos at E9.5.
Note the robust expression of Mef2c in the first and second branchial
arches.
(C–H) Dlx5, Dlx6, and Hand2 expression are nearly absent in the bran-
chial arches ofMef2c neural crest knockout embryos at E9.5. Note that
(F) Dlx6 expression is still faintly detected in the first arch of Mef2c
neural crest knockout embryos, and that (D and H) Dlx5 and Hand2
expression appears to be absent, except in a small region at the distal
tip of the first arch.
(I and J) X-Gal staining of E9.5 embryos generated by crossing
a ROSA26R lacZ reporter allele into the Mef2c conditional knockout
background showed no obvious defects in neural crest contribution
to the branchial arches or craniofacial mesenchyme compared to litter-648 Developmental Cell 12, 645–652, April 2007 ª2007 Elsevier Ia single gene-targeting event (Depew et al., 2002). Hetero-
zygosity for either Mef2c or Dlx5/6 alone did not signifi-
cantly affect neonatal viability (Figure 4A). By contrast,
100% of double heterozygous offspring were obviously
sick at birth and died on postnatal day 0 (P0) (Figure 4A),
indicating a clear genetic interaction between the Dlx5/6
and Mef2c loci. Compared to wild-type littermates,
Dlx5/6+/;Mef2c+/ mice exhibited a small, incomplete
palate and a displaced tongue (Figures 4B and 4C), which
is consistent with the palate and displaced tongue
phenotype in Mef2c NC conditional knockout mice
(Figure 1D); these results further support the conclusion
that MEF2C functions as a transcriptional activator and
partner of Dlx5 and Dlx6 in craniofacial development
(Figure 4D).
DISCUSSION
A MEF2-Dependent Transcriptional Pathway
for Craniofacial Development
We have uncovered a novel role for MEF2C function in the
NC as an essential regulator of craniofacial development.
The defects in Mef2c NC knockout mice are similar to
those found in other transcription factor knockouts, in-
cludingPrx1,Dlx5/6, andHand2 knockout animals (Bever-
dam et al., 2002; Depew et al., 2002; Martin et al., 1995;
Yanagisawa et al., 2003). We show that Dlx5, Dlx6, and
Hand2 expression are dramatically reduced in Mef2c
NC knockout embryos, and we present evidence that
MEF2C is a direct transcriptional regulator of Dlx5/6 via
a novel branchial arch enhancer. Additionally, we show
that Mef2c and Dlx5/6 genetically interact and that
MEF2C functions as a transcriptional partner with Dlx5
in a feed-forward transcriptional circuit by synergistically
activating a novel branchial enhancer in the Dlx5/6 locus
(Figure 4D).
Modular Control of Branchial Arch Gene Regulation
It has been noted previously that deletion of the Hand2
branchial arch enhancer does not completely abolish
Hand2 expression in the branchial arches, as a small re-
gion of distal expression within the arches appears to be
governed by a hypothetical, unidentified regulatory ele-
ment (Charite et al., 2001; Ruest et al., 2004; Yanagisawa
et al., 2003). Interestingly, the loss of Hand2 expression
seen in the absence of Mef2c function in the NC is nearly
complete, except at the distal end of the first arch, which
appears to correspond to the Dlx6-independent Hand2
expression domain (Figure 2H) (Yanagisawa et al., 2003).
Thus, Hand2 regulation, even within the branchial arches,
appears to be controlled by multiple enhancer modules
(Charite et al., 2001; Ruest et al., 2004; Yanagisawa
et al., 2003). Similarly, a previously identified intergenic
Dlx5/6 enhancer directs expression to the forebrain and
to a subset of the endogenous Dlx5 and Dlx6 expression
mate controls. Red arrowheads mark the first branchial arch in all
panels; asterisks mark craniofacial ectomesenchymal expression.nc.
Developmental Cell
MEF2C Is Required for Craniofacial DevelopmentFigure 3. Identification of a MEF2-Dependent Transcriptional Enhancer from the Dlx5/6 Locus
(A) Schematic representation of theDlx5/6 locus. Red boxes denote theDlx5 andDlx6 transcribed regions; arrows show the direction of transcription.
The blue box denotes the location of the enhancer identified in this study.
(B) ClustalW alignment of the mouse, human, and chicken sequences in the conserved region of the Dlx6 branchial arch enhancer. Conserved MEF2
consensus elements are highlighted by light-blue boxes, and conserved Hox/Dlx-binding sites are highlighted by yellow-green boxes; asterisks
denote conservation across all three species.
(C) The Dlx5/6 enhancer directs lacZ expression to the first and second branchial arches in transgenic embryos at E9.5, as shown by whole-mount
X-Gal staining. The arrowhead indicates branchial arch expression of the Dlx5/6-lacZ transgene.
(D) MEF2C trans-activates the Dlx5/6 branchial arch enhancer. Cotransfection of a MEF2C-VP16 expression plasmid with the Dlx5/6-TK-lacZ results
in 12-fold activation of the reporter (lane 4). This activation is dependent on the presence of the MEF2 sites since mutation of those elements almost
completely abolished MEF2 trans-activation (lane 6). No trans-activation of the parent reporter by MEF2C-VP16 was observed (lane 2). Data are
presented as the mean plus standard error for six independent experiments.
(E) MEF2C and Dlx5 synergistically activate the Dlx5/6 enhancer. Cotransfection of a MEF2C or Dlx5 expression plasmid results in 3-fold and 50-fold
activation, respectively, of the Dlx5/6 enhancer (lanes 4 and 5). Cotransfection of both expression plasmids results in strong synergistic activation of
over 400-fold (lane 6). No trans-activation of the TK parent reporter by MEF2C plus Dlx5 was observed (lane 2). Data are presented as the mean plus
standard error for three independent experiments.patterns in the branchial arches (Ruest et al., 2003; Zeru-
cha et al., 2000). Here, we identify an additional regulatory
module immediately upstream of the proposed Dlx6 tran-
scriptional start site that regulates expression in the
branchial arches (Figure 3). This type of compartmental-
ized regulation provides the opportunity for independent
control of gene expression in discrete lineages or for the
intersection of multiple, different upstream pathways in
the same lineage.DeveloMEF2C as a Potential Downstream Effector
of Endothelin Signaling
Dlx6 and Hand2 expression in branchial arch NC requires
endothelin signaling (Charite et al., 2001; Clouthier et al.,
2000; Ruest et al., 2004; Thomas et al., 1998). Endothelin
signaling regulates a diverse array of normal developmen-
tal and physiological processes, including cardiovascular
and craniofacial development in the embryo and vascular
tone postnatally (Clouthier et al., 1998; Kedzierski andpmental Cell 12, 645–652, April 2007 ª2007 Elsevier Inc. 649
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naling is also critical in a number of pathological pro-
cesses as well, including hypertension, atherosclerosis,
and pathological cardiac hypertrophy and heart failure
(Kedzierski and Yanagisawa, 2001). Targeted inactivation
of any one of several endothelin pathway components, in-
cluding Edn1, Ednra, and Ece1, results in lethality at birth
due to craniofacial defects and mechanical asphyxiation.
These phenotypes are similar to those exhibited by
Mef2c NC knockout mice and also include loss of Dlx6
and Hand2 expression (Charite et al., 2001; Clouthier
et al., 1998, 2000; Kurihara et al., 1994; Ruest et al.,
2004; Thomas et al., 1998; Yanagisawa et al., 1998).
Figure 4. Mef2c and Dlx5/6 Interact Genetically
(A) Mef2c+/ mice were crossed to Dlx5/6+/ mice, and the total num-
ber of offspring was scored on P0 (‘‘# born’’). Among the total of each
genotype born, animals were scored as either alive and viable (‘‘#
alive’’) or as dead or clearly cyanotic and dying (‘‘# dead/dying’’).
Nearly all wild-type,Mef2c+/, and Dlx5/6+/mice were viable at birth.
By contrast, 100% (9/9) Dlx5/6+/;Mef2c+/ mice died or were clearly
cyanotic on P0, indicating a strong genetic interaction.
(B andC) Sagittal sections of the heads of (B) wild-type or (C)Dlx5/6+/;
Mef2c+/ mice collected on P0. Compared to wild-type littermates,
Dlx5/6+/;Mef2c+/ mice exhibit a misshapen (arrowheads) and in-
complete (asterisk) palate and an improper position of the tongue at
the rear of the oral cavity.
(D) A model transcriptional pathway for craniofacial development in
which MEF2C functions downstream of endothelin receptor A signal-
ing to activate Dlx5 and Dlx6, which, in turn, activate Hand2 and also
reinforce their own expression in a feed-forward fashion. Solid arrows
denote direct regulation; dashed arrows denote direct or indirect
regulation.650 Developmental Cell 12, 645–652, April 2007 ª2007 ElsevierBased on these observations, it will be interesting to
determine if MEF2C functions as a downstream effector
of endothelin signaling during craniofacial development
(Figure 4D).
Implications for MEF2C Involvement in Congenital
Craniofacial Defects
Craniofacial defects are among the most common serious
congenital anomalies in humans, affecting as many as 1 in
every 300 births (Stanier and Moore, 2004). However, the
affected genes and developmental mechanisms underly-
ing the majority of craniofacial disorders remain unknown
(Stanier andMoore, 2004). This is likely due to the fact that
many craniofacial anomalies with a genetic component
are highly variable in penetrance or severity, several pres-
ent as part of broader syndromes, and some craniofacial
defects are thought to result from combinations of en-
vironmental and genetic influences (Farlie et al., 2004;
Stanier and Moore, 2004). For example, Pierre Robin se-
quence (PRS) is characterized by hypoplastic mandible,
a cleft palate, and obstruction of the upper airway by the
tongue (Dinwiddie, 2004; Farlie et al., 2004). The etiology
of PRS is thought to be primarily environmental in nature,
although there is evidence for a genetic component to this
complex and to broader syndromes that include the PRS
phenotypes (Dinwiddie, 2004; Farlie et al., 2004). Mice
lacking Mef2c function in the NC appear to have a similar
set of defects in the oral cavity, including a small lower jaw,
a cleft palate, and displacement of the tongue, suggesting
the possibility that developmental processes regulated by
MEF2C may contribute to this or other similar craniofacial
defects in humans.
EXPERIMENTAL PROCEDURES
Cloning and Mutagenesis
The Dlx6 enhancer fragment described in these studies was amplified
from mouse genomic DNA by using the primers Dlx6-F, 50-CCACCAC
ACAAGCTTGCTACCCCACAC-30, and Dlx6-R, 50-TGTGTTCAGAAGC
AGGGGCCCTAG-30, and were then cloned into plasmids Hsp68-lacZ
and pTK-b-gal for transgenic and transfection analyses, respectively.
Mutagenesis was performed as described previously (Dodou et al.,
2003). The sequences of the mutagenic oligonucleotides and other
oligonucleotides used for cloning are available upon request.
Transgenic Mice
Transgenic mice were generated by oocyte microinjection by using
standardmethods (Hogan et al., 1994) as described previously (Dodou
et al., 2003). Mef2c mutant mice carrying the Mef2cflox allele and the
conventional knockout allele, Mef2cTm1, have each been described
(Lin et al., 1997; Vong et al., 2005).Wnt1-Cre, Dlx5/6+/, and Rosa26R
lacZ reporter mice have also each been described (Danielian et al.,
1998; Depew et al., 2002; Soriano, 1999). Transgenic and knockout
alleles were detected by Southern blot. All experiments with animals
complied with federal and institutional guidelines and were reviewed
and approved by the University of California, San Francisco, Institu-
tional Animal Care and Use Committee.
X-Gal Staining, In Situ Hybridization, and Skeleton Preparations
X-Gal staining to detect b-galactosidase expression was performed as
described previously (Dodou et al., 2003). In situ hybridization was per-
formed according to standard methods by using digoxigenin-labeled
antisense probes as described previously (Rojas et al., 2005). SkeletonInc.
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procedures (Hogan et al., 1994).
Cell Culture and Transfections
3T3 cells were maintained in DMEM supplemented with 10% FBS.
Transfections were performed with FuGene 6 (Roche), according to
the manufacturer’s recommendations, in 35 mm dishes. A total of
1 mg each of reporter and expression plasmid was used in each trans-
fection so that the quantity of DNA was always held constant at 2 mg
per sample. Cells were cultured for 48 hr after transfection, harvested,
and assayed by using the Luminescent b-gal Detection System (Clon-
tech), as described previously (Dodou et al., 2003). Plasmid pRK5-
MEF2C contains the mouse MEF2C cDNA in the pRK-5 mammalian
expression vector (BD PharMingen). Plasmid pRK5-MEF2C-VP16 is
the same, except that the Herpesvirus VP16 activation domain has
been fused in-frame to the C terminus of theMEF2C coding sequence.
Supplemental Data
Supplemental Data include additional analysis of Dlx6 and Hand2
expression and analyses of Prx1 expression, apoptosis, and prolifera-
tion in Mef2c conditional knockout and control animals and are avail-
able at http://www.developmentalcell.com/cgi/content/full/12/4/645/
DC1/.
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